MiMedx Group, Inc.
Quick facts
Phase 3 pipeline
- Micronized dHACM · Wound Care / Regenerative Medicine
Micronized dehydrated human amnion/chorion membrane (dHACM) provides a biologic scaffold that promotes tissue regeneration and wound healing through growth factors and extracellular matrix components.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about MiMedx Group, Inc.
What is MiMedx Group, Inc.'s pipeline?
MiMedx Group, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Micronized dHACM.
Related
- Sector hub: All tracked pharma companies